August 7, 2005 -- Biotech scored three new highs in a row last week, though it backed off in the final two sessions, ending the week with a small net loss. In an early August consolidation of its huge July gains, the Centient Biotech 200 lost some 4 points or .13% of its value over the five sessions, closing at 3730.26. UTD Therapeutics climbed 25% on a good Q2 report, Myogen was up 24% on an analyst upgrade, Protein Design Labs rose 19.5% on a new collaboration and good earnings, MannKind jumped on a successful add-on financing, and Advanced Life Sciences managed to come public, though at a much reduced price. More details...
